<?xml version='1.0' encoding='utf-8'?>
<document id="18437385"><sentence text="Carbamazepine induces bioactivation of cyclophosphamide and thiotepa."><entity charOffset="0-13" id="DDI-PubMed.18437385.s1.e0" text="Carbamazepine" /><entity charOffset="39-55" id="DDI-PubMed.18437385.s1.e1" text="cyclophosphamide" /><entity charOffset="60-68" id="DDI-PubMed.18437385.s1.e2" text="thiotepa" /><pair ddi="false" e1="DDI-PubMed.18437385.s1.e0" e2="DDI-PubMed.18437385.s1.e0" /><pair ddi="false" e1="DDI-PubMed.18437385.s1.e0" e2="DDI-PubMed.18437385.s1.e1" /><pair ddi="false" e1="DDI-PubMed.18437385.s1.e0" e2="DDI-PubMed.18437385.s1.e2" /><pair ddi="false" e1="DDI-PubMed.18437385.s1.e1" e2="DDI-PubMed.18437385.s1.e1" /><pair ddi="false" e1="DDI-PubMed.18437385.s1.e1" e2="DDI-PubMed.18437385.s1.e2" /></sentence><sentence text="We report a patient with metastatic breast cancer who received three cycles of high-dose chemotherapy with cyclophosphamide [1,000 mg/(m(2) day)], thiotepa (80 mg/(m(2) day) and carboplatin (dose calculated based on modified Calvert formula with 3"><entity charOffset="107-123" id="DDI-PubMed.18437385.s2.e0" text="cyclophosphamide" /><entity charOffset="178-189" id="DDI-PubMed.18437385.s2.e1" text="carboplatin" /><pair ddi="false" e1="DDI-PubMed.18437385.s2.e0" e2="DDI-PubMed.18437385.s2.e0" /><pair ddi="false" e1="DDI-PubMed.18437385.s2.e0" e2="DDI-PubMed.18437385.s2.e1" /></sentence><sentence text="25 mg min/ml as daily target AUC) over 4 days, followed by peripheral blood progenitor cell support" /><sentence text=" During the first two cycles the patient concomitantly used carbamazepine for the treatment of epilepsy"><entity charOffset="60-73" id="DDI-PubMed.18437385.s4.e0" text="carbamazepine" /></sentence><sentence text=" Due to severe nausea and vomiting the patient was unable to ingest carbamazepine; therefore, this was discontinued after the second cycle"><entity charOffset="68-81" id="DDI-PubMed.18437385.s5.e0" text="carbamazepine" /></sentence><sentence text="" /><sentence text="Blood samples were drawn on 2 days (day 1 and 2, 3 or 4) of each cycle and plasma levels of cyclophosphamide, its active metabolite 4-hydroxycyclophosphamide, thiotepa, its main, active metabolite tepa and carboplatin were determined"><entity charOffset="92-108" id="DDI-PubMed.18437385.s7.e0" text="cyclophosphamide" /><entity charOffset="132-157" id="DDI-PubMed.18437385.s7.e1" text="4-hydroxycyclophosphamide" /><entity charOffset="159-167" id="DDI-PubMed.18437385.s7.e2" text="thiotepa" /><entity charOffset="197-201" id="DDI-PubMed.18437385.s7.e3" text="tepa" /><entity charOffset="206-217" id="DDI-PubMed.18437385.s7.e4" text="carboplatin" /><entity charOffset="163-173" id="DDI-PubMed.18437385.s7.e5" text="tepa" /><pair ddi="false" e1="DDI-PubMed.18437385.s7.e0" e2="DDI-PubMed.18437385.s7.e0" /><pair ddi="false" e1="DDI-PubMed.18437385.s7.e0" e2="DDI-PubMed.18437385.s7.e1" /><pair ddi="false" e1="DDI-PubMed.18437385.s7.e0" e2="DDI-PubMed.18437385.s7.e2" /><pair ddi="false" e1="DDI-PubMed.18437385.s7.e0" e2="DDI-PubMed.18437385.s7.e5" /><pair ddi="false" e1="DDI-PubMed.18437385.s7.e0" e2="DDI-PubMed.18437385.s7.e3" /><pair ddi="false" e1="DDI-PubMed.18437385.s7.e0" e2="DDI-PubMed.18437385.s7.e4" /><pair ddi="false" e1="DDI-PubMed.18437385.s7.e1" e2="DDI-PubMed.18437385.s7.e1" /><pair ddi="false" e1="DDI-PubMed.18437385.s7.e1" e2="DDI-PubMed.18437385.s7.e2" /><pair ddi="false" e1="DDI-PubMed.18437385.s7.e1" e2="DDI-PubMed.18437385.s7.e5" /><pair ddi="false" e1="DDI-PubMed.18437385.s7.e1" e2="DDI-PubMed.18437385.s7.e3" /><pair ddi="false" e1="DDI-PubMed.18437385.s7.e1" e2="DDI-PubMed.18437385.s7.e4" /><pair ddi="false" e1="DDI-PubMed.18437385.s7.e2" e2="DDI-PubMed.18437385.s7.e2" /><pair ddi="false" e1="DDI-PubMed.18437385.s7.e2" e2="DDI-PubMed.18437385.s7.e5" /><pair ddi="false" e1="DDI-PubMed.18437385.s7.e2" e2="DDI-PubMed.18437385.s7.e3" /><pair ddi="false" e1="DDI-PubMed.18437385.s7.e2" e2="DDI-PubMed.18437385.s7.e4" /><pair ddi="false" e1="DDI-PubMed.18437385.s7.e5" e2="DDI-PubMed.18437385.s7.e5" /><pair ddi="false" e1="DDI-PubMed.18437385.s7.e5" e2="DDI-PubMed.18437385.s7.e3" /><pair ddi="false" e1="DDI-PubMed.18437385.s7.e5" e2="DDI-PubMed.18437385.s7.e4" /><pair ddi="false" e1="DDI-PubMed.18437385.s7.e3" e2="DDI-PubMed.18437385.s7.e3" /><pair ddi="false" e1="DDI-PubMed.18437385.s7.e3" e2="DDI-PubMed.18437385.s7.e4" /></sentence><sentence text="" /><sentence text="Exposure to 4-hydroxycyclophosphamide and tepa on day 1 was increased in the presence of carbamazepine (58 and 75%, respectively), while exposure to cyclophosphamide and thiotepa was reduced (40 and 43%, respectively)"><entity charOffset="12-37" id="DDI-PubMed.18437385.s9.e0" text="4-hydroxycyclophosphamide" /><entity charOffset="42-46" id="DDI-PubMed.18437385.s9.e1" text="tepa" /><entity charOffset="89-102" id="DDI-PubMed.18437385.s9.e2" text="carbamazepine" /><entity charOffset="149-165" id="DDI-PubMed.18437385.s9.e3" text="cyclophosphamide" /><entity charOffset="170-178" id="DDI-PubMed.18437385.s9.e4" text="thiotepa" /><entity charOffset="174-181" id="DDI-PubMed.18437385.s9.e5" text="tepa" /><pair ddi="false" e1="DDI-PubMed.18437385.s9.e0" e2="DDI-PubMed.18437385.s9.e0" /><pair ddi="false" e1="DDI-PubMed.18437385.s9.e0" e2="DDI-PubMed.18437385.s9.e1" /><pair ddi="false" e1="DDI-PubMed.18437385.s9.e0" e2="DDI-PubMed.18437385.s9.e2" /><pair ddi="false" e1="DDI-PubMed.18437385.s9.e0" e2="DDI-PubMed.18437385.s9.e3" /><pair ddi="false" e1="DDI-PubMed.18437385.s9.e0" e2="DDI-PubMed.18437385.s9.e4" /><pair ddi="false" e1="DDI-PubMed.18437385.s9.e0" e2="DDI-PubMed.18437385.s9.e5" /><pair ddi="false" e1="DDI-PubMed.18437385.s9.e1" e2="DDI-PubMed.18437385.s9.e1" /><pair ddi="false" e1="DDI-PubMed.18437385.s9.e1" e2="DDI-PubMed.18437385.s9.e2" /><pair ddi="false" e1="DDI-PubMed.18437385.s9.e1" e2="DDI-PubMed.18437385.s9.e3" /><pair ddi="false" e1="DDI-PubMed.18437385.s9.e1" e2="DDI-PubMed.18437385.s9.e4" /><pair ddi="false" e1="DDI-PubMed.18437385.s9.e1" e2="DDI-PubMed.18437385.s9.e5" /><pair ddi="false" e1="DDI-PubMed.18437385.s9.e2" e2="DDI-PubMed.18437385.s9.e2" /><pair ddi="false" e1="DDI-PubMed.18437385.s9.e2" e2="DDI-PubMed.18437385.s9.e3" /><pair ddi="false" e1="DDI-PubMed.18437385.s9.e2" e2="DDI-PubMed.18437385.s9.e4" /><pair ddi="false" e1="DDI-PubMed.18437385.s9.e2" e2="DDI-PubMed.18437385.s9.e5" /><pair ddi="false" e1="DDI-PubMed.18437385.s9.e3" e2="DDI-PubMed.18437385.s9.e3" /><pair ddi="false" e1="DDI-PubMed.18437385.s9.e3" e2="DDI-PubMed.18437385.s9.e4" /><pair ddi="false" e1="DDI-PubMed.18437385.s9.e3" e2="DDI-PubMed.18437385.s9.e5" /><pair ddi="false" e1="DDI-PubMed.18437385.s9.e4" e2="DDI-PubMed.18437385.s9.e4" /><pair ddi="false" e1="DDI-PubMed.18437385.s9.e4" e2="DDI-PubMed.18437385.s9.e5" /></sentence><sentence text="" /><sentence text="Since increased exposure to the active metabolites is associated with an increased risk of toxicity, it is important to be aware of this drug-drug interaction" /><sentence text="" /></document>